Symptomatic treatment remains central to the clinical management of Alzheimer disease (AD) and continues to provide immediate benefit for cognition, everyday function and behavioural symptoms. This role persists even as disease-targeted therapies emerge that aim to alter long-term disease trajectory. The evidence base covers both non-pharmacological approaches and pharmacological agents; the collective aim is to improve quality of life while complementary disease-modifying strategies are developed and implemented.
Non-pharmacological interventions consistently show modest but reproducible effects on cognition and related outcomes. Approaches with the strongest supporting evidence include cognitive training, structured physical exercise, cognitive stimulation therapy and multimodal lifestyle programmes that combine several behavioural components. The benefits reported tend to be small-to-moderate in magnitude and are most apparent in people with mild cognitive impairment or early-stage disease.
Implementation challenges limit the clinical impact of these interventions. Scalability, adaptation to diverse clinical settings, sustained adherence, and ensuring equitable access are repeatedly identified barriers. Comparisons across trials are complicated by heterogeneity in intervention content, intensity, duration and outcome measurement. Where reported, computerized cognitive training and structured multidomain programmes have demonstrated measurable cognitive improvements, but detailed effect sizes and long-term durability are not provided in the available summary.
Existing pharmacological symptomatic treatments provide modest yet clinically meaningful benefits. The mainstays remain cholinesterase inhibitors and memantine, which have demonstrated efficacy in randomized trials and meta-analyses. Meta-analytic data on cholinesterase inhibitors have evaluated discontinuation, efficacy and safety across many randomized trials; these agents continue to be recommended as part of symptomatic management for appropriate patients.
Recent analyses that stratify participants by biomarker status (for example, blood- or CSF-based markers confirming AD pathology) suggest that responsiveness to established symptomatic drugs may be greater in individuals with confirmed AD pathology. This emerging biomarker-informed perspective supports more precise symptomatic therapeutics, although full implementation details and operational thresholds for clinical use were not provided in the summary.
Research to broaden symptomatic benefit is focusing on targets beyond classical cholinergic and glutamatergic mechanisms. Next-generation approaches include muscarinic agonists, agents acting at the σ1 receptor, serotonergic modulators and neurotrophic pathway modulators. Multitarget molecules and repurposed drugs are also under investigation with the intent of modulating neurotransmitter systems and neural circuits implicated in cognition and behaviour.
These advances open opportunities for circuit-level modulation and potentially wider symptomatic effects, but the summary does not present detailed efficacy or safety outcomes for specific novel compounds. Ongoing development emphasises combining mechanistic rationale with biomarker-informed selection to increase the probability of clinically meaningful benefit.
Neuropsychiatric symptoms are highly prevalent in AD and are a major source of distress for patients and caregivers. Tailored, personalised psychosocial interventions demonstrate meaningful reductions in agitation and depressive symptoms and are recommended as first-line approaches where feasible.
Pharmacological management remains necessary in many cases, but conventional atypical antipsychotics offer only modest efficacy and carry substantial safety concerns. Newer agents have been developed and trialled for specific neuropsychiatric indications: for example, brexpiprazole has been evaluated for agitation associated with dementia, and pimavanserin has been studied for psychosis in neurodegenerative disease. These agents show promise, with potentially more favourable safety considerations than older atypical antipsychotics, but interpretation requires caution regarding effect size and safety profile; the summary does not provide detailed comparative effect estimates or long-term safety data.
Key priorities for future progress include:
The field also recognises the potential value of repurposed drugs and multitarget compounds as components of combination regimens, although operational frameworks for testing and implementing such combinations were not detailed in the summary.
Symptomatic therapies will remain essential in the care of people living with AD, delivering immediate and measurable benefits while disease-modifying treatments evolve. Both non-pharmacological approaches and established pharmacological agents provide modest but important improvements in cognition, function and neuropsychiatric symptoms. Emerging therapeutics and biomarker-stratified strategies offer opportunities to refine and expand symptomatic benefit. Continued emphasis on implementation, scalability, safety and patient-centred outcomes is needed to translate trial findings into improved real-world care.
(Note: This summary is based on the abstract, key points and available preview material from the cited review. Full article details, specific effect sizes, trial results and comprehensive safety data were not available in the provided source text.)